Effective January 1, 2025, the following intravenous (IV) Iron supplementation products will be preferred by Independence Blue Cross (IBX):
- Ferumoxytol (e.g., Feraheme®)
- Infed iron dextran (e.g., INFeD®)
- Iron sucrose (e.g., Venofer®)
- Sodium ferric gluconate complex in sucrose (e.g., Ferrlecit®)
Updates to precertification requirements
Injectafer® and Monoferric® will be added to the precertification list and will be considered second-line, non-preferred IV Iron products for IBX Commercial and Medicare Advantage members. This means that members must try two of the generic IV Iron products prior to moving to Injectafer or Monoferric.
Requests for preferred IV Iron supplements INFeD, Venofer, Ferrlecit, and Feraheme still will not require precertification approval from IBX.
Learn more
These changes will be reflected in updated Commercial and Medicare Advantage medical policies in January 2025:
- Commercial:
- #08.02.29: Intravenous (IV) Iron Preparations
- Medicare Advantage:
- #MA08.150: Intravenous (IV) Iron Preparations
To view any pending policy notifications (which signify upcoming changes) or active medical policies, you can visit the IBX Medical and Claim Payment Policy Portal.
Under Active Notifications or Policy Bulletins, select Commercial or Medicare Advantage, based on which version of the policy you want to view. Then, you can search by category or type the policy name or number in the Search box up top. For more information on accessing medical policies, refer to our article on Staying updated on Medical Policies.